Literature DB >> 8240435

Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La.

H Julkunen1, P Kurki, R Kaaja, R Heikkilä, I Immonen, E K Chan, E Wallgren, C Friman.   

Abstract

OBJECTIVE: To study the long-term outcome of mothers of children with isolated congenital heart block (CHB) and to characterize the maternal autoantibody response to SS-A/Ro and SS-B/La.
METHODS: A retrospective clinical study of 33 mothers a mean of 11.2 years (SD 9.2 years, range 0-32 years) after the delivery of their first child with CHB. A clinical and immunologic study of 31 of these mothers, compared with 89 healthy mothers, 45 mothers with systemic lupus erythematosus (SLE), and 19 mothers with primary Sjögren's syndrome (SS), all of whom had healthy children. The specificity of the autoantibody responses to SS-A/Ro and SS-B/La was studied by enzyme-linked immunosorbent assays using purified human recombinant antigens and affinity-purified antigens.
RESULTS: By the time of the analysis, 2 (6%) of the 33 mothers of CHB children had died and 6 (18%) had met the criteria for SLE. As a group, mothers of CHB children had clinical and immunologic characteristics more closely related to primary SS than to SLE or any other connective tissue disease. The predominant autoantibody response was to the SS-A/Ro antigens, notably to the 52-kd SS-A/Ro protein (prevalence 97%). Compared with controls with SLE, mothers of CHB children had higher titers of antibodies to recombinant 52-kd and 60-kd SS-A/Ro proteins and to the affinity-purified SS-A/Ro antigen (P < 0.05, P < 0.01, and P < 0.001, respectively). Compared with controls with primary SS, the autoantibody responses were similar.
CONCLUSION: The predominant autoimmune disorder in mothers of children with CHB is subclinical primary SS. Antibodies to SS-A/Ro appear to be a prerequisite for the development of CHB.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8240435     DOI: 10.1002/art.1780361114

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

Review 1.  Sjögren Syndrome and Pregnancy: A Literature Review.

Authors:  Suruchi Gupta; Nikhil Gupta
Journal:  Perm J       Date:  2016-11-09

Review 2.  Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk.

Authors:  J P Buyon; R M Clancy; D M Friedman
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

Review 3.  Prenatal evaluation and management of fetuses exposed to Anti-SSA/Ro antibodies.

Authors:  Anita Krishnan; Jodi I Pike; Mary T Donofrio
Journal:  Pediatr Cardiol       Date:  2012-05-22       Impact factor: 1.655

Review 4.  Neonatal lupus.

Authors:  Antonio Brucato; Rolando Cimaz; Marco Stramba-Badiale
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

5.  Cardiac manifestations in primary Sjögren's syndrome.

Authors:  M Gyöngyösi; G Pokorny; Z Jambrik; L Kovács; A Kovács; E Makula; M Csanády
Journal:  Ann Rheum Dis       Date:  1996-07       Impact factor: 19.103

Review 6.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

7.  Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus.

Authors:  T L Rivera; P M Izmirly; B K Birnbaum; P Byrne; J B Brauth; M Katholi; M Y Kim; J Fischer; R M Clancy; J P Buyon
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103

8.  Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block.

Authors:  L Strandberg; O Winqvist; S-E Sonesson; S Mohseni; S Salomonsson; K Bremme; J P Buyon; H Julkunen; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

9.  Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus.

Authors:  E D Silverman; J Buyon; R M Laxer; R Hamilton; P Bini; J L Chu; K B Elkon
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

Review 10.  Neonatal lupus: clinical features and management.

Authors:  Lela A Lee
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.